申请人:Gilead Sciences, Inc.
公开号:US11352371B2
公开(公告)日:2022-06-07
The present disclosure relates generally to thienopyrimidine compounds that bind to Acetyl-CoA Carboxylase (ACC) and act as inhibitors of ACC. The disclosure further relates to the use of the thienopyrimidine compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of ACC, including liver diseases such as non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).
本公开一般涉及与乙酰-CoA 羧化酶(ACC)结合并作为 ACC 抑制剂的噻吩嘧啶化合物。本公开进一步涉及噻吩嘧啶化合物用于制备通过与 ACC 结合治疗疾病和/或病症的药物,包括肝脏疾病,如非酒精性脂肪肝(NAFLD)和非酒精性脂肪性肝炎(NASH)。